The United Kingdom and the United States have announced a major trade agreement that will preserve no import taxes on British pharmaceutical shipments going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to boost spending on medicines through the NHS. This move secures that import taxes on these vital goods will be held at nothing for a period of three years.
This deal is in response to previous warnings to significantly raise import taxes on patented drug imports, with increases discussed as high as 100%.
"This arrangement between the Britain reinforces the worldwide climate for new treatments and brings much-needed fairness to transatlantic drug exports," an announcement said.
Economic Importance
Medicines constitute one of the the United Kingdom's biggest exports to the United States, which is by far the largest destination for major companies like GSK and AstraZeneca.
Statistics indicate that in the year leading up to last September, the UK exported medicines worth over eleven billion pounds to the US. This value represented nearly one-fifth of British export trade in that period.
"This deal protects employment, boosts funding and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The pact entails several key pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to control costs will be restricted at 15%. Last year, refunds exceeded 20%.
Broader Context
This agreement comes amid a protracted dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were heightened by claims that US patients were paying significantly more for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or cancelled, while major funding commitments have been directed toward projects in the United States.
The Science Minister stated that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
